Nature's Sunshine (NATR)

Wellness products company Nature’s Sunshine (NASDAQ:NATR) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $123.8 million. The company’s full-year revenue guidance of $507.5 million at the midpoint came in 2.6% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 57.9% above analysts’ consensus estimates.

Company Overview

Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products.

While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.

Competitors offering health and wellness supplements and products include Herbalife (NYSE:HLF), USANA Health Sciences (NYSE:USNA), Bellring Brands (NYSE:BRBR), and The Simply Good Foods Company (NASDAQ:SMPL).

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years.

With $480.1 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.

As you can see below, Nature's Sunshine’s sales grew at a tepid 4.4% compounded annual growth rate over the last three years. This shows it failed to generate demand in any major way and is a rough starting point for our analysis.

This quarter, Nature's Sunshine reported modest year-on-year revenue growth of 4.7% but beat Wall Street’s estimates by 1.8%.

Looking ahead, sell-side analysts expect revenue to grow 3.1% over the next 12 months, similar to its three-year rate. This projection doesn't excite us and indicates its products will see some demand headwinds.

At StockStory, we prefer high gross margin businesses because they indicate pricing power or differentiated products, giving the company a chance to generate higher operating profits.

Nature's Sunshine has best-in-class unit economics for a consumer staples company, enabling it to invest in areas such as marketing and talent to grow its brand. As you can see below, it averaged an elite 72% gross margin over the last two years. That means Nature's Sunshine only paid its suppliers $28.05 for every $100 in revenue.

In Q4, Nature's Sunshine produced a 72.5% gross profit margin, in line with the same quarter last year. Zooming out, the company’s full-year margin has remained steady over the past 12 months, suggesting its input costs (such as raw materials and manufacturing expenses) have been stable and it isn’t under pressure to lower prices.

Operating margin is a key profitability metric because it accounts for all expenses enabling a business to operate smoothly, including marketing and advertising, IT systems, wages, and other administrative costs.

Nature's Sunshine’s operating margin has generally stayed the same over the last 12 months, averaging 4.8% over the last two years. This profitability was paltry for a consumer staples business and caused by its suboptimal cost structure.

Looking at the trend in its profitability, Nature's Sunshine’s operating margin might fluctuated slightly but has generally stayed the same over the last year. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

This quarter, Nature's Sunshine generated an operating margin profit margin of 4.3%, in line with the same quarter last year. This indicates the company’s cost structure has recently been stable.

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Nature's Sunshine’s EPS grew at 216% compounded annual growth rate over the last three years, higher than its 4.4% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its operating margin didn’t improve.

In Q4, Nature's Sunshine reported adjusted EPS of $0.30, up from $0 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Nature's Sunshine’s full-year EPS of $1.26 to shrink by 23.8%.

Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.

Nature's Sunshine has shown mediocre cash profitability relative to peers over the last two years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 4.6%, below what we’d expect for a consumer staples business.

Taking a step back, an encouraging sign is that Nature's Sunshine’s margin expanded by 2.9 percentage points over the last year. The company’s improvement shows it’s heading in the right direction, and we can see it became a less capital-intensive business because its free cash flow profitability rose while its operating profitability was flat.

Nature's Sunshine’s free cash flow clocked in at $7.56 million in Q4, equivalent to a 6.1% margin. The company’s cash profitability regressed as it was 2.3 percentage points lower than in the same quarter last year, but it’s still above its two-year average. We wouldn’t read too much into this quarter’s decline because investment needs can be seasonal, causing short-term swings. Long-term trends carry greater meaning.

EPS and free cash flow tell us whether a company was profitable while growing its revenue. But was it capital-efficient? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Although Nature's Sunshine hasn’t been the highest-quality company lately, it historically found a few growth initiatives that worked. Its five-year average ROIC was 16.8%, higher than most consumer staples businesses.

One of the best ways to mitigate bankruptcy risk is to hold more cash than debt.

Nature's Sunshine is a profitable, well-capitalized company with $93.89 million of cash and $18.9 million of debt on its balance sheet. This $74.99 million net cash position is 17.1% of its market cap and gives it the freedom to borrow money, return capital to shareholders, or invest in growth initiatives. Leverage is not an issue here.

It was good to see Nature's Sunshine beat analysts’ EPS expectations this quarter. We were also excited its EBITDA outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a solid print. The stock traded up 2.9% to $25.80 immediately following the results.

Updated: March 10, 2026 at 10:55 PM EDT

The latest quarterly earnings matters, sure, but we actually think longer-term fundamentals and valuation matter more. Investors should consider all these pieces before deciding whether or not to invest in Nature's Sunshine.

Nature's Sunshine’s business quality ultimately falls short of our standards. For starters, its revenue growth was a little slower over the last three years. While its admirable gross margins are a wonderful starting point for the overall profitability of the business, the downside is its brand caters to a niche market. On top of that, its projected EPS for the next year is lacking.

Nature's Sunshine’s P/E ratio based on the next 12 months is 22.8x. Investors with a higher risk tolerance might like the company, but we think the potential downside is too great. We're pretty confident there are superior stocks to buy right now.

Wall Street analysts have a consensus one-year price target of $28 on the company (compared to the current share price of $26.81).